50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
QQQ   271.04 (-3.18%)
AAPL   142.07 (-5.19%)
MSFT   235.22 (-2.43%)
META   137.31 (-3.04%)
GOOGL   96.28 (-3.77%)
AMZN   114.33 (-3.12%)
TSLA   268.09 (-6.85%)
NVDA   121.20 (-4.84%)
NIO   15.59 (-10.04%)
BABA   78.56 (-3.00%)
AMD   63.84 (-6.61%)
T   15.53 (-1.90%)
MU   49.80 (-2.35%)
CGC   2.83 (-6.91%)
F   11.47 (-5.83%)
GE   62.23 (-3.46%)
DIS   97.16 (-2.25%)
AMC   7.13 (-7.04%)
PYPL   89.02 (-2.30%)
PFE   44.29 (-0.32%)
NFLX   240.43 (-1.95%)
QQQ   271.04 (-3.18%)
AAPL   142.07 (-5.19%)
MSFT   235.22 (-2.43%)
META   137.31 (-3.04%)
GOOGL   96.28 (-3.77%)
AMZN   114.33 (-3.12%)
TSLA   268.09 (-6.85%)
NVDA   121.20 (-4.84%)
NIO   15.59 (-10.04%)
BABA   78.56 (-3.00%)
AMD   63.84 (-6.61%)
T   15.53 (-1.90%)
MU   49.80 (-2.35%)
CGC   2.83 (-6.91%)
F   11.47 (-5.83%)
GE   62.23 (-3.46%)
DIS   97.16 (-2.25%)
AMC   7.13 (-7.04%)
PYPL   89.02 (-2.30%)
PFE   44.29 (-0.32%)
NFLX   240.43 (-1.95%)
QQQ   271.04 (-3.18%)
AAPL   142.07 (-5.19%)
MSFT   235.22 (-2.43%)
META   137.31 (-3.04%)
GOOGL   96.28 (-3.77%)
AMZN   114.33 (-3.12%)
TSLA   268.09 (-6.85%)
NVDA   121.20 (-4.84%)
NIO   15.59 (-10.04%)
BABA   78.56 (-3.00%)
AMD   63.84 (-6.61%)
T   15.53 (-1.90%)
MU   49.80 (-2.35%)
CGC   2.83 (-6.91%)
F   11.47 (-5.83%)
GE   62.23 (-3.46%)
DIS   97.16 (-2.25%)
AMC   7.13 (-7.04%)
PYPL   89.02 (-2.30%)
PFE   44.29 (-0.32%)
NFLX   240.43 (-1.95%)
QQQ   271.04 (-3.18%)
AAPL   142.07 (-5.19%)
MSFT   235.22 (-2.43%)
META   137.31 (-3.04%)
GOOGL   96.28 (-3.77%)
AMZN   114.33 (-3.12%)
TSLA   268.09 (-6.85%)
NVDA   121.20 (-4.84%)
NIO   15.59 (-10.04%)
BABA   78.56 (-3.00%)
AMD   63.84 (-6.61%)
T   15.53 (-1.90%)
MU   49.80 (-2.35%)
CGC   2.83 (-6.91%)
F   11.47 (-5.83%)
GE   62.23 (-3.46%)
DIS   97.16 (-2.25%)
AMC   7.13 (-7.04%)
PYPL   89.02 (-2.30%)
PFE   44.29 (-0.32%)
NFLX   240.43 (-1.95%)
NASDAQ:KMDA

Kamada - KMDA Stock Forecast, Price & News

$4.43
-0.07 (-1.56%)
(As of 09/29/2022 12:50 PM ET)
Add
Compare
Today's Range
$4.36
▼
$4.44
50-Day Range
$4.44
▼
$5.43
52-Week Range
$4.22
▼
$6.96
Volume
1,135 shs
Average Volume
35,665 shs
Market Capitalization
$198.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KMDA stock logo

About Kamada (NASDAQ:KMDA) Stock

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

KMDA Stock News Headlines

September 23, 2022 | reuters.com
Kamada and Mitoma strike as Japan breeze past United States - Reuters
September 23, 2022 | nasdaq.com
Eli Lilly (LLY) Gets FDA Nod for RET Inhibitor in Solid Tumors - Nasdaq
September 22, 2022 | money.usnews.com
Bank of Japan Keeps Ultra-Low Rates, Dovish Policy Guidance - U.S News & World Report Money
September 21, 2022 | msn.com
Look away GSB: West Ham look to have made a big mistake - opinion - msnNOW
September 20, 2022 | nasdaq.com
AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication - Nasdaq
September 14, 2022 | nasdaq.com
Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer - Nasdaq
September 13, 2022 | washingtonpost.com
Frankfurt wins 1-0 at Marseille in CL game hit by disorder - The Washington Post
September 13, 2022 | nasdaq.com
FDA Panel to Review Perrigo's (PRGO) OTC Birth Control Pill - Nasdaq
September 9, 2022 | nasdaq.com
Amylyx (AMLX) Up 51% After FDA Committee Endorses ALS Drug - Nasdaq
September 7, 2022 | nasdaq.com
Clinical Hold on Sarepta's (SRPT) DMD Candidate Lifted by FDA - Nasdaq
September 5, 2022 | streetinsider.com
Alvotech Reports Update on Initial AVT02 Biologics License Application - StreetInsider.com
September 4, 2022 | barrons.com
Football: Leading German Bundesliga Scorers - Barron's
August 28, 2022 | usatoday.com
Stuttgart still winless after 0-0 draw at Cologne - USA TODAY
August 24, 2022 | streetinsider.com
Alvotech to Participate in Two Upcoming Investor Conferences in September 2022 - StreetInsider.com
August 17, 2022 | investing.com
Kamada Ltd. Misses Q2 EPS by 7c By Investing.com - Investing.com
August 17, 2022 | benzinga.com
Kamada: Q2 Earnings Insights - Benzinga
August 17, 2022 | globenewswire.com
Kamada Reports Second Quarter and First Half 2022 Financial Results; Significant Growth Driven by Multiple Catalysts Expected in Second Half of 2022; Reiterates 2022 Revenue and Profitability Guidance - GlobeNewswire
August 17, 2022 | finance.yahoo.com
Kamada (KMDA) Q2 Earnings Beat Estimates
August 17, 2022 | ca.investing.com
Kamada Ltd. Misses Q2 EPS by 7c By Investing.com - Investing.com Canada
August 17, 2022 | seekingalpha.com
Kamada GAAP EPS of -$0.09, revenue of $23.6M misses by $0.09M, reaffirms FY22 guidance - Seeking Alpha
August 17, 2022 | seekingalpha.com
Kamada Q2 2022 Earnings Preview (NASDAQ:KMDA) - Seeking Alpha
August 15, 2022 | finance.yahoo.com
Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8:00 am ET on September 1, 2022 - Yahoo Finance
August 15, 2022 | streetinsider.com
Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8:00 am ET on September 1, 2022 - StreetInsider.com
August 13, 2022 | usatoday.com
Hertha fans sing despite only drawing with Frankfurt 1-1 - USA TODAY
August 10, 2022 | benzinga.com
Kamada to Announce Second Quarter and First Half Ended June 30, 2022 Financial Results and Host Conferenc - Benzinga
See More Headlines
Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

KMDA Company Calendar

Last Earnings
11/21/2021
Today
9/29/2022
Next Earnings (Estimated)
11/28/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KMDA
CUSIP
N/A
CIK
1567529
Web
www.kamada.com
Phone
(728) 940-6472
Fax
972-8940-6473
Employees
355
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
221.50
P/E Growth
N/A
Net Income
$-2,230,000.00
Net Margins
-10.93%
Pretax Margin
-10.56%
Return on Equity
-2.32%
Return on Assets
-1.43%

Debt

Debt-to-Equity Ratio
0.09
Current Ratio
2.39
Quick Ratio
1.09

Sales & Book Value

Annual Sales
$103.64 million
Price / Sales
1.91
Cash Flow
$0.11 per share
Price / Cash Flow
41.62
Book Value
$3.95 per share
Price / Book
1.12

Miscellaneous

Outstanding Shares
44,800,000
Free Float
N/A
Market Cap
$198.46 million
Optionable
Not Optionable
Beta
0.97

Key Executives

  • Mr. Amir London (Age 53)
    Chief Exec. Officer
    Comp: $522k
  • Mr. Chaime Orlev (Age 52)
    Chief Financial Officer
    Comp: $331k
  • Mr. Eran Nir (Age 49)
    Chief Operating Officer
    Comp: $322k
  • Ms. Yifat Philip Esq. (Age 45)
    VP of Legal, Gen. Counsel & Corp. Sec.
    Comp: $247k
  • Mr. David Tsur (Age 72)
    Co-Founder & Deputy Chairman
  • Ms. Hanni Neheman (Age 52)
    VP of Marketing & Sales
  • Ms. Ariella Raban (Age 46)
    VP of HR
  • Mr. Jon R. Knight
    VP of US Commercial Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













KMDA Stock - Frequently Asked Questions

Should I buy or sell Kamada stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares.
View KMDA analyst ratings or view top-rated stocks.

How have KMDA shares performed in 2022?

Kamada's stock was trading at $6.58 at the beginning of the year. Since then, KMDA shares have decreased by 31.6% and is now trading at $4.50.
View the best growth stocks for 2022 here.

When is Kamada's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 28th 2022.
View our KMDA earnings forecast.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings results on Sunday, November, 21st. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.05. The biotechnology company earned $23.03 million during the quarter, compared to analyst estimates of $25.20 million. Kamada had a negative net margin of 10.93% and a negative trailing twelve-month return on equity of 2.32%. During the same quarter last year, the company earned $0.15 earnings per share.

What guidance has Kamada issued on next quarter's earnings?

Kamada updated its FY 2022 earnings guidance on Wednesday, September, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $125.00 million-$135.00 million, compared to the consensus revenue estimate of $83.67 million.

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

How do I buy shares of Kamada?

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $4.50.

How much money does Kamada make?

Kamada (NASDAQ:KMDA) has a market capitalization of $201.60 million and generates $103.64 million in revenue each year. The biotechnology company earns $-2,230,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

How many employees does Kamada have?

The company employs 355 workers across the globe.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The official website for the company is www.kamada.com. The biotechnology company can be reached via phone at (728) 940-6472, via email at ir@kamada.com, or via fax at 972-8940-6473.

This page (NASDAQ:KMDA) was last updated on 9/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.